A Phase I/II Clinical Trial of β‐Globin Gene Therapy for β‐Thalassemia
- 1 November 2005
- journal article
- research article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1054 (1), 308-316
- https://doi.org/10.1196/annals.1345.007
Abstract
Recent success in the long-term correction of mouse models of human β-thalassemia and sickle cell anemia by lentiviral vectors and evidence of high gene transfer and expression in transduc...This publication has 22 references indexed in Scilit:
- Integration of Retroviruses: A Fine Balance between Efficiency and DangerPLoS Medicine, 2005
- Successful correction of the human β-thalassemia major phenotype using a lentiviral vectorBlood, 2004
- LMO2and Gene Therapy for Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2004
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003
- Successful treatment of murine β-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cellsBlood, 2003
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003
- Correction of Sickle Cell Disease in Transgenic Mouse Models by Gene TherapyScience, 2001
- The effect of multidrug-resistance 1 gene versus neotransduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cellsBlood, 2001
- Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 DiseaseScience, 2000
- Human somatic cell gene therapyBioEssays, 1996